Stock-Based Compensation: The estimated market value of stock options, warrants and other stock-based compensation given to employees and/or vendors.
Telix Pharmaceuticals Limited (TLX) had Stock-Based Compensation of $19.35M for the most recently reported fiscal year, ending 2025-12-31.
| Income Statement Financials | |
$803.79M |
|
$-7.12M |
|
$377.36M |
|
$426.44M |
|
$774.02M |
|
$29.78M |
|
$-35.04M |
|
$-5.27M |
|
$-5.27M |
|
$-7.12M |
|
$-7.12M |
|
$-7.12M |
|
$-7.12M |
|
$29.78M |
|
$51.19M |
|
337.88M |
|
337.88M |
|
$-0.02 |
|
$-0.02 |
|
| Balance Sheet Financials | |
$330.28M |
|
$58.66M |
|
$833.71M |
|
$1.16B |
|
$231.62M |
|
$448.45M |
|
$516.99M |
|
$748.61M |
|
$415.38M |
|
$-177.45M |
|
$415.38M |
|
338.78M |
|
| Cash Flow Statement Financials | |
$-17.29M |
|
$-285.92M |
|
$-3.72M |
|
$440.00M |
|
$141.87M |
|
$-298.13M |
|
|
Stock-Based Compensation |
$19.35M |
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
1.43 |
|
-- |
|
-- |
|
0.52 |
|
1.12 |
|
53.05% |
|
3.70% |
|
3.70% |
|
6.37% |
|
-0.66% |
|
-0.89% |
|
$-42.98M |
|
-- |
|
-- |
|
-- |
|
0.69 |
|
10.18 |
|
6.22 |
|
58.67 |
|
-1.72% |
|
4.02% |
|
-0.61% |
|
-0.82% |
|
$1.23 |
|
$-0.13 |
|
$-0.05 |
|